Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Melanoma × soluble LAG-3 protein, human × Clear all

Phase

Phase 1/2 2 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2 Peritoneal Neoplasms 1 Melanoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1

Interventions

pembrolizumab 82 Nivolumab 50 Ipilimumab 50 Cyclophosphamide 50 fludarabine 25 Vemurafenib 24 aldesleukin 23 Interleukin-2 23 trametinib 19 fludarabine phosphate 19 dabrafenib 15 Biopsy 14 Temozolomide 13 Cisplatin 12 atezolizumab 11 spartalizumab 10 Introns 10 poly ICLC 9 cobimetinib 9 Specimen Handling 9 Radiosurgery 9 MART-1 Antigen 9 Carboplatin 9 incomplete Freund's adjuvant 8 Radiotherapy 8 Radiation 8 Paclitaxel 8 Magnetic Resonance Spectroscopy 8 Filgrastim 8 Docetaxel 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02676869 2019-12-18

TACTI-mel

Immutep Australia Pty. Ltd.

Phase 1 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡